Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof

US11591372B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter L. Collins · Kensington, US
• Bo Liang · Maoming, CN
• Shirin Munir · Bethesda, US
• Anne Schaap Nutt · Austin, US
• Ursula Buchholz · Silver Spring, US
• Natalie Mackow · East Setauket, US
• Peter Kwong · Washington, US
• Barney Graham · Rockville, US
• Jason McLellan · Austin, US

Key dates

• Filing date: May 18, 2020
• Grant date: Feb 28, 2023
• Expiry date: Nov 24, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18771
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.